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ABSTRACT 
Yen Bao Pham: Characterization of a tryptophanyl-tRNA synthetase Urzyme and its 
intramolecular complementation establishes a model to study the catalytic mechanism and 
evolution of the contemporary Class I aminoacyl-tRNA synthetases 
(Under the direction of Charles W. Carter, Jr.) 
 
Aminoacyl-tRNA synthetases (AaRSs) comprise a crucial group of enzymes 
catalyzing a two-step reaction to activate amino acids and acylate their cognate 
tRNAs. It is widely known that highly conserved sequences and motifs divide the 
synthetases evenly into two distinct classes of ten members each. However, the 
questions of how they might have emerged and evolved and what a reasonable 
candidate for the ancestral enzyme would be like still remain unsolved. Answering 
these would not only shed light on the aaRSs evolution but could also help unravel the 
critical point when the extremely high kinetic barrier of amino acid activation was 
bypassed, allowing the synthesis of primitive peptide chains.  
The research object of the studies is a tryptophanyl-tRNA synthetase (TrpRS) 
Urzyme (Ur-: prefix means primitive, original) which would fit the description of a 
potential candidate for the ancestral class I aaRS. The TrpRS Urzyme is designed to 
retain class I signature sequences that comprise the ATP-binding Rossmann fold. 
Interestingly, it has similar affinity for ATP compared to the full length wild type 
enzyme but surprisingly low affinity for the cognate amino acid substrate, tryptophan. 
This might be explained by absence of the connecting peptide 1 (CP1), an insertion 
that wraps around the tryptophan binding site in the contemporary enzyme and occurs 
at the same location as the editing domain in four other class I aaRSs (MetRS, LeuRS, 
IleRS, ValRS). An in cis modular complementation experiment might point out a 
 iv 
 
potential role for CP1 in configuring a confirmation that has high affinity for 
tryptophan, functionally similar to a primitive proofreading function. Furthermore, an 
Urzyme containing the C-terminal domain (CTD) in cis has been constructed to 
further explore CTD’s role in tryptophan activation and tRNATrp acylation. 
The active TrpRS Urzyme establishment confirms an essential prediction of, and 
is therefore, the first experiment to provide evidential support for the unique Rodin-
Ohno hypothesis about the earlier existence of a sense-antisense coding system for 
both aaRS classes. The successful design of the TrpRS Urzyme has also provided a 
precedent that has led to the construction of class I and class II aaRS Urzymes of 
comparable lengths. 
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CHAPTER I 
 
INTRODUCTION
  
2 
Aminoacyl-tRNA Synthetases Play a Crucial Role in Various Biological Processes
     The major function of these enzymes, as suggested by their names, is to synthesize 
specific aminoacyl-tRNAs (II) (Carter, 1993). The first half of this reaction, amino 
acid activation by ATP (I), is the rate limiting step among those required for protein 
synthesis on the ribosome since this is the only means whereby the free amino acids 
can be activated and linked with their cognate carriers. It is important to note that (I) 
occurs at a slow rate of 8.3 x 10−9/mol/s (as corrected from the published value of 7 x 
10−6/mol/min for reaction at pH 9.7, 39°C for a similar reaction (Kirby and Younas 
1970) in the absence of this biological catalyst due to its high activation energy 
barrier. Hence, the emergence of aaRS enzymes is a very significant step in launching 
the evolution of protein synthesis.  
aaRS + ATP + aa => aa-AMP-aaRS + PPi  (I) 
aa-AMP-aaRS + tRNA => aa-tRNA + AMP + aaRS   (II) 
An intriguing characteristic of aaRS is that they can be either accurate or 
ambiguous depending on the enzyme’s ability to recognize its cognate substrates, or 
in other words, its specificity. There exists an internal domain called the editing 
domain in some aaRSs that corrects the formation of misacylated amino acids through 
hydrolysis, thus further ensuring the fidelity of genetic code in translation. Editing-
defective aaRSs have been shown to cause unfaithful translation, misfolding and 
neurodegeneration (Lee et al., 2006). On the other hand, the flexibility of the same 
enzyme provides materials for evolutionary changes in protein engineering (Link et 
al., 2003). The introduction of different amino acids other than the twenty limited to 
natural proteins by a promiscuous aaRS is the major step in expanding the current 
genetic code. Two non-canonical amino acids, selenocysteine and pyrrolysine, coined 
the 21st and 22nd amino acid, respectively, have been found encoded by codons once 
 3 
thought to be non-sense, stop triplets. Associated with these new amino acids are 
aaRSs that have evolved respectively, from seryl and lysyl tRNA synthetases (Zhang 
et al., 2005).  
As summarized in Figure 1, beside their aminoacylation activity, aaRSs have been 
recently linked to a number of biological processes (Park et al., 2006). These include 
signaling pathways in human, in which the Class Ic tryptophanyl and tyrosyl 
synthetases play angiogenic and antiangiogenic roles, respectively (Wakasugi et al., 
2002; Yang, 2004; Tzima et al., 2005). More interestingly, the assembly of different 
aaRSs in a multi-aaRS complex (MSC) has been shown to be involved in cell death 
(apoptosis) (Hausmann and Ibba, 2008). In a different biological process, studies by 
Fox et al. (2008) pointed out that the WHEP domain of glutamyl-prolyl-tRNA 
synthetase (EPRS) plays a dual role in inflammation-responsive, transcript-selective 
translational silencing. Importantly, according to Musier-Forsyth et al. (2006), HIV 
virion assembly requires formation of a packaging complex which contains tRNALys, 
substrate of lysyl-tRNA synthetase (LysRS), and the synthetase itself. Implications of 
aaRSs in a variety of diseases, including cancer, Alzheimer’s (Paley et al., 2007), 
Charcot Marie-Tooth neuropathy (Seburn et al., 2006) make understanding both the 
aaRSs structure and the mechanism a significant object for the pharmaceutical 
industry. 
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Figure 1: Connections of aaRSs in various biological processes showing their 
potential in medical treatments (Park et al., 2006). 
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My dissertation aims to answer two major questions, the first regarding aaRS 
modular complementation (intramolecular interactions), and the second about its 
evolution by constructing a novel tryptophanyl-tRNA synthetase Urzyme (Ur-: suffix 
for primitive, original). As the name suggests, an Urzyme is a construct designed to 
represent an early stage in the evolution of a contemporary enzyme. It consists of a 
minimal catalytic domain with sufficient stability to fold and which retains enough of 
the active site to show a considerable fraction of the catalytic activity of the native 
protein. 
Structural Composition of Contemporary AaRS and Its Classification 
Based on structure and catalytic mechanism, twenty contemporary aaRSs are 
classified into either class I or class II, each consisting of ten members. Class I aaRSs 
are defined by their two signature sequences of Lys-Met-Ser-Lys-Ser (KMSKS) and 
His-Iso-Gly-His (HIGH) while three conserved regions, motifs 1, 2 and 3 make class 
II’s identity. Further studies divide each class into three subclasses a, b and c (Eriani 
et al., 1990; Carter, 1993; Cavarelli et al., 1994). The structures of the members in 
each subclass are similar, judging from superimposition. The non-random homology 
in structures and mechanism raises an unsolved question of how the enzymes might 
have evolved. The question is even more complicated upon factoring in the existence 
of the internal and external insertions in between the highly conserved sequences and 
motifs.  
The Emergence of Aminoacyl-tRNA Synthetases 
Molecular evolution is a field that draws a lot of attention. The evolutionary 
standpoint allows researchers to investigate the past, while also opening doors to the 
future through modeling and prediction (Dean and Thornton, 2007). It is widely 
accepted that primitive proteins were small and simply structured, and that they
 6 
 gradually acquired multi-domain, multi-function form through evolution. 
Catalytically active proteins, enzymes, have probably evolved most profoundly under 
the pressure to be a more efficient catalyst. This evolution could be achieved by 
various means, e.g. gene duplication, domain fusion, substrate binding pocket 
reconfiguration.  
The aaRSs are a dynamic class of enzyme. One can see the emergence of new 
ways to increase aminoacylation activity in living organisms. The activity of one 
aaRS might increase several times in the presence of another (Prætorius-Ibba, Rogers 
et al., 2005). In a similar way, different fusion forms of aaRSs have been found to 
have dual activity (Sampath et al., 2004). Furthermore, some aaRSs have been shown 
to be associated with an elongation factor at the site of ribosomal protein synthesis 
which would enhance the efficiency of the process (Hausmann and Ibba, 2007). These 
are the results of recent studies on different aaRSs focusing on intermolecular 
interactions. However, the intramolecular interactions among aaRS structural domains 
still raise many unresolved questions that need to be answered to unravel the 
concerted catalytic mechanism. 
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Figure 2: Postulated evolution scheme of aminoacyl-tRNA synthetase from a 
primitive form to the contemporary complex fusions (Pham, unpublished). 
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Besides the continuing dynamic changes, there is evidence about the insertions of 
functional domains from a distant past. Larger aaRSs possess different internal and 
external insertions. These insertions include the connecting peptides 1 and 2, the 
anticodon binding domain and other structures of unknown functions (Burbaum, 
Starzyk, and Schimmel, 1990). Connecting peptide 1 probably is one of the best 
characterized insertions. It has been shown that the editing domain in four 
contemporary class I aaRSs (MetRS, LeuRS, IleRS,ValRS) probably originated by 
elaboration from the connecting peptide 1 insertion. The carboxyl-terminal anticodon 
binding domain and other RNA-interacting elements were also likely introduced later 
in evolution. Some groups have dissected parts of these domains to construct minimal 
aaRSs (Schwob and Soll, 1993; Augustine and Francklyn, 1997). However, no study 
has been done to find out how ancestral catalysts might have emerged from the 
presumably small and simpler peptides. A postulated scheme for aaRS evolution is 
depicted in Figure 2. 
This question becomes more interesting and more complicated since there are two 
different classes of contemporary aaRSs. Would they be the products of divergent or 
convergent evolution? Rodin and Ohno have postulated a unique hypothesis regarding 
the emergence of aaRSs from two strands of one ancestral gene (Figure 3).  
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Figure 3: Alignment of class I and class II aaRSs most highly conserved motifs 
and sequences showing a sense-antisense homology relationship as an illustration 
for Rodin-Ohno hypothesis (adapted from Pham et al., 2007). 
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This work on the TrpRS Urzyme confirms a key prediction of the Rodin-Ohno 
hypothesis (Rodin and Ohno, 1995) that ancestral Class I enzymes must have been 
functional without the CP1 insertion. As such, it provides the first experimental 
evidence to support that hypothesis and introduces procedures that may be useful to 
characterize and study the Urzymes of other multi-domain proteins. As shown in 
Figure 3, the CP1 insertion (corresponding to the editing domain in four aaRSs) and 
the C-terminal anticodon-binding domain were removed to reveal a minimal catalytic 
core that comprises the TrpRS Urzyme. The computational construction phase and the 
significant activity from a refolded TrpRS Urzyme will be discussed in the second 
chapter. The third chapter is focused on the investigation of a suitable expression 
system to solubilize the Urzyme. Using an optimized system, Michaelis-Menten 
kinetics for the Urzyme are characterized and will be presented in the fourth chapter. 
Modular Complementation Starting with a Core Urzyme to Understand the 
Intramolecular Interactions 
I have made two additional constructs, in which the connecting peptide 1 and the 
C-terminal anticodon-binding domain are located in cis relative to the core TrpRS 
Urzyme. An immediate future direction of the dissertation is to investigate the role of 
those two domains in amino acid activation, specificity and acylation of tRNATrp. 
These studies are intended to support the idea that the contemporary enzyme may 
once have existed as a simple peptide chain that acquired additional functional 
domains through later insertions in evolution. 
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Figure 4: Modular fragments designed to examine the complementation of 
TrpRS Urzyme. A, C: two discrete halves of the Rossmann ATP binding domain 
(colored gray). B: connecting peptide 1 (green), a 74-residue long peptide insertion 
between A and C fragments. D: C-terminal anticodon binding domain (yellow). ABC, 
ACD: constructs containing TrpRS Urzyme and B and D in cis, respectively. (Pham, 
unpublished). 
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CHAPTER 2 
 
A RE-DESIGNED, CATALYTICALLY ACTIVE TRYPTOPHANYL-
TRNA SYNTHETASE URZYME LACKING THE ANTICODON-BINDING 
DOMAIN AND AN INTERNAL 76-RESIDUE PEPTIDE PROVIDES THE 
FIRST EXPERIMENTAL EVIDENCE FOR THE SENSE/ANTISENSE 
CODING ANCESTRY OF CLASS I AND CLASS II AMINOACYL-TRNA 
SYNTHETASES 
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Abstract 
 
Every protein starts from the translation of codons in messenger RNA into a chain 
of amino acids. There are twenty contemporary aminoacyl-tRNA synthetases (AaRS) 
initiating the assembly of polypeptide chains by catalyzing the formation of covalent 
cognate amino acid – transfer RNA adducts so that the protein building blocks can be 
carried to the ribosomal machinery for protein synthesis. It is well established that 
these enzymes belong to two different superfamilies called class I and class II aaRS, 
each consisting of 10 members. Tryptophanyl-tRNA synthetase is the smallest 
member of class I aaRS, possessing two signature sequences TIGN and KMSKS that 
form its active site. Interestingly, this active site is separated by a connecting peptide 
(CP1) that, when removed in silico using computational design, leaves a gap of only 5 
Ångstrom. Using computational algorithms, a stable minimal catalytic domain, 
designated the TrpRS Urzyme (Ur- : prefix means primitive, original), has been 
designed by fusing the two active site segments after removing CP1 and the C-
terminal anticodon binding domain (CTD). Pyrophosphate exchange assays have 
showed significant amino acid activation activity for the molecule whose size is only 
one sixth that of the active dimer. TrpRS Urzyme may have evolved by acquiring 
other domains later in evolution. Further experiments are to be done to validate this 
minimal catalytic domain as a candidate for an ancestral TrpRS gene (this chapter is 
adapted from Pham et al., 2007). 
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Introduction 
 
Proteins, especially enzymes, have been intensively studied since the beginning of 
life sciences due to their universal participation in every biological process. A widely 
accepted common model for protein synthesis by ribosomes has been well 
established.  However, the evolution of the polypeptide synthesizing machinery is still 
an unresolved area. One prevailing hypothesis postulates the existence of an “RNA 
world”. Supporters of the RNA world hypothesis are struggling to find RNA capable 
of amino acid activation. This reaction is kinetically very slow, or in other words, 
needs a great amount of energy to reach transition state (Kumar and Yarus, 2001). 
The activated amino acid is by definition a reactive species and hence reacts rapidly, 
about 10 million times more than amino acid activation. Thus, peptide bond formation 
from activated amino acids proceeds rather fast compared to amino acid activation by 
ATP, which is very slow, and the actual rate limiting step in protein synthesis is the 
activation of the amino acids. Acylation of tRNA is also much more rapid than amino 
acid activation. Hence, aminoacyl-tRNA synthetases, the contemporary enzymes 
catalyzing this difficult task, are the most important missing catalysts in the big 
picture linking the postulated primitive RNA world and the present proteome. 
Aminoacyl-tRNA synthetases are the solution for rate enhancement in living 
organisms. The crucial role of AaRSs in protein synthesis is comparable with DNA 
polymerase in replication (Francklyn, 2008). Polymerases have a large rate 
enhancement (i.e., they are very good catalysts) and they also ensure faithful copying 
of the genetic messages, both in replication and transcription. Similarly, in addition to 
accelerating the rate of amino acid activation, aaRSs also recognize both their cognate 
amino acids and tRNAs.  It has been shown that five aaRSs possess an editing 
capability that enhances the fidelity of translation. Since protein synthesis is common 
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to every organism, aaRSs can be used to construct a phylogenetic tree. New codon 
translations are introduced when this proofreading activity is compromised. 
AaRSs use energy from adenosine triphosphate in a two-step reaction to activate 
free amino acids (I) then acylate the cognate tRNAs (II) to form aminoacyl-tRNAs for 
protein synthesis on the ribosome.  
                        aaRS + ATP + aa => aa-AMP-aaRS + PPi                       (I) 
               aa-AMP-aaRS + tRNA => aa-tRNA + AMP + aaRS             (II) 
The twenty canonical aaRSs are divided into two classes, depending on structural 
and mechanistic characteristics. Ten members in class I aaRS have two signature 
loops, KMSKS and HIGH, which are parts of the Rossmann fold (whose core is a 
parallel β-sheet flanked by α-helices) responsible for the ATP and tRNA acceptor 
stem binding. On the other hand, ATP and tRNA interaction sites of class II aaRSs 
that form the anti-parallel β-sheet core consist of different combinations of three 
degenerate sequence motifs. Among those, motif 2, ΦΦΦ+ΦxxxFRxE/D (Φ: 
hydrophobic residue), is shared by all members (Carter, 1993). Based on structure and 
reaction mechanism, ten aaRSs in each class are also divided into subclasses a, b and 
c, with subclass a being the largest, containing aaRSs for six amino acids in each case, 
and subclass c being the smallest, containing aaRSs for the aromatic amino acids.  
Interestingly, the catalytic cores of class I and class II aaRSs shown in Figure 5 
consist of only 120-130 amino acids.              
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Figure 5: The cores of Class I and Class II aminoacyl-tRNA synthetases. 
Approximately 120-130-residue long peptides carved out from conserved class I 
signatures HIGH and KMSKS and class I motifs 2 and 1, then aligned in opposite 
directions (Carter lab, unpublished). 
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Most class I aaRSs bind the tRNA acceptor stem from the minor groove side and 
acylate the 2’-OH group of the terminal base whereas most class II aaRSs bind to the 
major groove side and acylate the 3’-OH group (Eriani et al., 1990; Carter, 1993; 
Ribas de Pouplana and Schimmel, 2001). One common feature of class I enzymes is 
that their active form is usually monomeric. In contrast, most class II enzymes are 
active only in oligomeric form and in which motif 1 contributes essentially to a dimer 
interface. The consistency within each class and the distinction between the two 
classes make the above classification widely accepted. However, there is little 
evidence for a common ancestor for both classes and no explanation about the 
evolutionary class separation.  
All class I aaRSs contain an insertion between the two halves of the ATP binding 
Rossmann fold. This insertion is called “Connecting Peptide 1” (CP1) (Starzyk, 
Burbaum et al., 1989). In the smallest class Ic aaRS, tryptophanyl-tRNA synthetase 
(TrpRS), this insertion has 76 residues. In four of the large class Ia aaRSs (LeuRS, 
MetRS, IleRS, ValRS), the corresponding internal insertion has grown bigger in size 
into a more structured domain harboring an editing function that is specific for the 
most frequently mistaken amino acid (Jakubowski and Goldman, 1992). Similarly, the 
carboxyl-terminal anticodon binding domain might have evolved from a shorter 
primitive ancestral peptide as a later addition. Rodin and Ohno have proposed a 
unique hypothesis to explain the emergence of contemporary aaRSs based on 
sequence alignments. They found that the coding sequences for the HIGH and 
KMSKS class I signatures are very nearly antisense to the corresponding coding 
sequences of the class I motifs 2 and 1, respectively (Rodin and Ohno, 1995).  They 
noted that when all of the intervening insertions are removed, the KMSKS and HIGH 
loops from class I aaRSs can be aligned approximately antiparallel with motifs 1 and 
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2 from class II aaRSs as sense and antisense strands of one gene. The earliest aaRS 
would have been active enzymes; otherwise they could not have participated in 
natural selection. The Rodin/Ohno observation therefore suggests directly that a 
constructed gene lacking CP1 should be enzymatically active. However, no 
experiment has been done to test this hypothesis. 
In this chapter, an experiment that characterizes a redesigned, catalytically active 
TrpRS Urzyme consistent with Rodin and Ohno’s observation will be discussed as the 
first experimental evidence supporting Rodin-Ohno hypothesis. Using computational 
algorithms, a 130-residue long Urzyme has been constructed by removing the internal 
76 residues connecting peptide and truncating the carboxyl-terminal domain. This 
Urzyme shows significant activity in catalyzing amino acid activation compared to 
the native enzyme.  
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Materials and Methods 
Linker Design to Replace Connecting Peptide 1 
TrpRS Urzyme was constructed in silico by fusing two halves of the Rossmann 
fold. The connecting peptide 1, a 74-residue long fragment between T46 and G121, 
and the last 124 amino acids at the carboxyl-terminal domain were removed. The 
resulting 130-residue long sequence was submitted to Rosetta Design (Dantas et al., 
2003; Kuhlman and Baker, 2004; Schueler-Furman et al., 2005; Dantas et al., 2006) 
with six linkers (A, AA, AGA, AAAA, AAGAA, AGAAGA) that vary in length and 
consist of short side chain amino acids alanine (A) and glycine (G). A zero length 
linker was also included. Up to 4 residues adjacent to each side of CP1 removal were 
allowed to mutate to facilitate restoration of molecular continuity. For each linker, 
sixty backbones were pulled out of the biological database in the Protein Data Bank 
(PDB) with assigned energy scores as the indicator for stability measurement. 
Solvent Accessible Surface Area (SASA) Analysis to Improve Solubility 
The solvent accessible surface area was compared between TrpRS Urzyme and 
the native full-sized enzyme in three different conformations, the open unliganded 
state, the transition state and the closed liganded product state, using Areaimol 
(CCP4, 1991). A threshold value of +50 Å2 was set as limit for the exposure of 
hydrophobic residues caused by CP1 and ABD removal to identify the residues that 
would be subjected to mutation by Rosetta Design. The predicted mutations were 
introduced to TrpRS Urzyme in addition to the previously selected in the CP1 loop 
closure. Genes for two TrpRS Urzymes amino acid sequences either with or without 
these additional mutations designated redesigned (DES) and wild type (WT), 
respectively, were synthesized by Genscipt and optimized to eliminate rare codons. 
Bacterial Strains and Plasmid Construction 
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Restriction enzymes and other molecular biology reagents were obtained from 
New England Biolabs and were used according to the manufacturer's protocols. 
Forward and reverse primers for PCR amplification were designed to be 
complementary to the Urzyme sequence, containing extra nucleotides coding for N-
terminal FLAG and C-terminal 6xHIS tags. Desired restriction sites were also 
introduced in the primer design step. Following digestion with the appropriate 
enzymes, the PCR products were cloned into E.coli expression plasmid pET-42a for 
use in bacterial strain BL21(DE3)pLysS (Novagen). The D146A mutant in the DES 
fragment was prepared using the Invitrogen GeneTailor Site-Directed Mutagenesis 
System. All constructs were confirmed by DNA sequencing. 
Protein Expression 
All TrpRS fragments were expressed directly after transforming with plasmid 
DNA. After transformation, 100 µl competent cells were incubated in 1ml LB media 
at 37°C for 1 hr with shaking and then used to inoculate 100 ml growth media (LB 
plus 2% glucose, 30 µg/ml kanamycin, 34 µg/ml chloramphenicol). The inoculum 
was shaken at 250 rpm overnight at 37°C and then transferred to 1 l fresh LB with 30 
µg/ml kanamycin and 34 µg/ml chloramphenicol. At OD600 = 0.4–0.8, isopropyl-β-D-
thiogalactopyranoside (IPTG) was added to 1 mM final concentration to induce gene 
expression. Harvest began 14 hr after induction. 
Purification of Fragments from Supernatant and Inclusion Bodies 
Cell-free extract was prepared from frozen cell pellets by lysing cells in 50 mM 
Tris, 10% sucrose (pH 7.5), using a continuous flow pressure cell (Avestin), followed 
by centrifugation at 20,000 rpm for 30 min at 4°C, and the pellets were re-extracted in 
the same manner. Supernatants were combined and centrifuged at 27,500 rpm for 1 hr 
to yield the soluble fraction. The pellet (inclusion bodies) from this step and the 
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combined supernatant were used as starting materials for purification. The soluble 
fraction was then dialyzed against anti-FLAG washing buffer (1× PBS, 0.05% 
Tween-20, 5 mM ATP, 50 µM tryptophan, 10% glycerol, 50 mM KCl, 0.1 mM 
EDTA, 5 mM β-mercaptoethanol, 4 mM MgCl2 [pH 7.8]). 
Renaturation from Inclusion Bodies 
Optimized renaturation conditions were determined from an incomplete factorial 
design (Chester et al., 2004;  Yin and Carter, 1996) of nine different sets of conditions 
in which the temperature, protein concentration, KCl concentration, pH, dialysis 
protocol, and presence of substrates were varied randomly and rebalanced. Inclusion 
bodies were first dissolved and diluted in solubilization buffer (20 mM HEPES [pH 
7.8], 6 M urea, 50 mM or 250 mM KCl, 5 mM MgCl2, 1 mM EDTA, 1 mM PMSF, 1 
mM β-mercaptoethanol, 5% glycerol [Campbell and Carpenter, 1995] with and 
without substrates) to OD280 = 2–10 (approximate total protein concentration of 2–10 
mg/ml). Supernatants after further centrifugation (17,000 rpm for 30 min at 4°C) were 
dialyzed three times against ten volumes of the same buffer at 4° or 37°C, without 
urea. Before the final dialysis, bags were opened and 10 µl of anti-FLAG beads 
(Sigma) were added per ml of protein. FLAG-bound material was eluted in the same 
solution with 50 µg/ml of FLAG peptide solution. Multiple regression of specific 
activities against the experimental variables identified three factors (low protein 
concentration, high pH, and low KCl concentration) responsible for (R2 = 0.87) of the 
variation in the data with t test probabilities of 104. 
Purification on Anti-FLAG Resin Beads 
Prewashed anti-FLAG bead suspension was added (10 µl/ml) to supernatants, 
which were shaken overnight at 4°C. Fragments bound to the beads (recovered in 
Bio-Rad Hi-Trap Q columns) were eluted with FLAG peptide (0.5 µl/ml). 
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Quantitation of Specific Activity 
Both immunoblotting with anti-FLAG antibody and silver staining were used to 
construct standard curves for estimating protein concentrations. As the silver-stained 
gels showed that the samples were quite pure, we determined most concentrations by 
using silver staining. 
32PPi Exchange Assays for Tryptophan Activation 
Fragment and empty-vector eluates from anti-FLAG beads were concentrated 8- 
to 25-fold before being assayed. Samples were assayed using the traditional 32P-
pyrophosphate exchange as described (Joseph and Muench, 1971) except that a 3-fold 
reduction of background 32P counts was achieved by collecting the charcoal 
containing labeled ATP on disposable spin columns, washing, and eluting the bound 
ATP with 50 µl of pyridine at 37°C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 23 
Results 
Computational Phase to Design a Linker to Ensure TrpRS Urzyme Molecular 
Continuity 
Based on the multiple sequence alignments (MSA) of known class I and class II 
aaRSs, a gene encoding the highly conserved residues in two disjoint TrpRS 
Rossmann fold fragments has been constructed (Pham et al., 2007). In this 130-amino 
acid Urzyme, the connecting peptide (CP1) is removed and the C-terminal domain is 
truncated, thereby exposing the molecule to two anticipated problems: structural 
disruption at the site of CP1 removal and, more severely, instability and/or 
insolubility due to the loss of two thirds of its stable configuration. Using the Rosetta 
algorithm, a short linker of varying length, from 0 to 6 residues, containing short side 
chain amino acids alanine and glycine, has been scanned to ensure molecular 
continuity. Furthermore, three residues adjacent to the sites of T46 and G121 were 
allowed to mutate (backbone melting), facilitating the joining of two free ends. The 
Rosetta Design program assigned lowest energy score for the direct linkage between 
threonine and glycine, indicating that a stable construct could be possible without 
inserting any residue into the gap created by removing CP1 (Figure 6). This construct 
had five mutations, created by allowing relaxed backbones, illustrated by the blue 
spheres at the site of removal (Figure 7A). 
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Figure 6: The Rosetta energy profile shows a decisively lower energy score for most 
constructs of 130-residue long after CP1 and CTD truncation. The lowest energy of 
these constructs, with zero length linker (direct linkage between T46 and G121) and 
five relaxed side chains adjacent to the site of connecting peptide 1 removal (Pham, 
unpublished) constituted the wild type Urzyme.  
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Solubilizing and Stabilizing the Wild Type TrpRS Urzyme 
To address expected instability and insolubility problems, the profile of the 
accessible surface area (ASA) for each residue in the computationally simulated 
Urzyme has been compared with the native enzyme using Areaimol (CCP4, 1991). 
From 60 positively increased ASA values, indicating changes in exposure due to the 
removal of CP1 and the ABD, the 19 highest were selected and submitted to Rosetta 
for mutation suggestion (Table 1). It should be noted that, excepting Tyr91, none of 
these mutations involved highly conserved residues (Table 2). 
Amino acid Residue ∆S(PROD) ∆S(PreTS) ∆S(Open) 
VAL 13 9 99 19 
ILE 14 85 71 102 
ILE 16 57 62 58 
TYR 19 98 74 83 
LEU 23 57 56 63 
TYR 36 90 86 65 
PHE 37 84 88 95 
ILE 39 124 127 124 
LEU 122 132 120 89 
LEU 123 115 119 117 
LEU 135 130 119 112 
TYR 136 87 81 91 
LEU 153 64 58 56 
LEU 157 52 55 51 
PHE 161 72 75 76 
TYR 165 89 80 74 
LEU 168 75 76 69 
LEU 186 105 91 109 
ILE 204 114 119 134 
 
Table 1: Comparison of solvent accessible surface area between WT Urzyme and 
full length TrpRS in three different configurations. PROD: product-bound, Pre-
TS: pre transition state, Open: unliganded (Carter, unpublished).  
 
The second Urzyme, called the redesigned (DES), harboring 12 mutations 
predicted   by   Rosetta   to   increase   solubility and stability is the result of the final  
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Figure 7: Two TrpRS Urzyme constructs after computational design. A: wild 
type Urzyme (WT) retains native sequence plus five mutated residues at the site of 
CP1 removal. B: redesigned Urzyme (DES) harboring twelve mutations (see Table 2) 
predicted to improve stability and solubility (adapted from Pham et al., 2007). 
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computational processing step (Figure 7B). This redesigned Urzyme has a total 
number of 17 mutations compared to the native sequence (Table 2). 
 
 
 
 
 
 
 
 
 
 
 
Table 2: List of all mutations introduced to the TrpRS Urzymes including 
five residues which were changed from hydrophobic to hydrophilic in the wild 
type (WT) and redesigned (DES) Urzymes, respectively (bold). Free energy 
differences ()
 
were also calculated showing minimal effect of the mutations (Pham et 
al., 2007). A ∆Gstat of less than 0.45 is a measure of relative sequence conservation as 
defined by Lockless et al., 1999.  
 
Expression and Purification of a Potentially-toxic Urzyme  
The target sequence for WT and DES TrpRS Urzymes were synthesized and 
delivered in pUC57 by Genscript. This expression system is known for a high copy 
number, between 150 and 200, which would result in higher expression level of the 
protein of interest. However, the Urzyme is likely to be toxic for the cells due to the 
predicted low specificity. Thus, a lower copy number plasmid system was desired. 
pET42, a system derived from pUC57, was chosen for expression. With 15-20 copies 
of the plasmid per cell, the protein of interest would be less highly expressed which 
might affect the total yield but increase the Urzyme stability.  
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Figure 8: pET 42 a (+) expression vector showing relative positions of 
elements introduced. The open reading frame (ORF) of the TrpRS Urzyme genes 
was tagged with an N-terminal FLAG and a C-terminal 6xHIS (Pham, unpublished). 
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Two tags were introduced to facilitate detection and purification of the enzyme. 
The final expression system is shown in the Figure 8. pET 42a (+) containing the 
target gene is transformed into BL21(DE3) pLysS; this expression system has lower 
basal expression due to inhibition of T7 RNA polymerase by lysozyme, minimizing 
potential toxicity of the desired product prior to induction. 
TrpRS Urzyme Expressed in the pET42a System Was Insoluble 
Using an incomplete factorial design, an optimized expression condition was set 
for the TrpRS Urzymes (Table 3, blue). As showed in Figure 14 below, the amount of 
soluble Urzyme could not be detected with immunoblotting which is more sensitive 
than Coomassie Blue or silver staining methods. This indicated that the DES TrpRS 
Urzyme, after designed modification, was still unstable in the supernatant fraction.  
 
Sample 
 
Temperature 
(0C) 
EtOH 
(%v) 
Induction 
time (hr) 
Pellet 
weight (g) 
Band 
intensity 
1 15 0 4 0.27 5 
2 15 0.064 6.7 0.26 0 
3 15 0.04 12.1 0.25 4 
4 15 0 20 0.28 6 
5 15 0.08 20 0.24 0 
6 25 0.08 4 0.24 0 
7 25 0.013 10.4 0.38 7 
8 25 0.044 15.9 0.27 3 
9 37 0.034 4 0.33 8 
10 37 0.08 11.5 0.23 2 
11 37 0 14.1 0.43 10 
12 37 0.045 20 0.23 3 
 
Table 3: Expression condition optimization for the TrpRS Urzymes. The 11th 
sample (blue) had highest yield measured. 
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                                                       M       T        P        S 
Figure 9: Fractionation of TrpRS Urzyme in the supernatant (S) and the 
inclusion bodies pellet (P) compared with total yield (T). The Urzyme was 
immunoblotted with anti-FLAG antibodies and showed as the expected molecular 
weight (arrow position) (Pham, unpublished data). 
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Renaturation was Efficient to Solubilize the Redesigned, but Not the Wild Type 
Urzyme 
Since most of the Urzyme was in the inclusion bodies, a refolding method using 
urea to dissolve the pellet was chosen to recover the fragment in soluble form. Using 
the same incomplete factorial design method, 9 different combinations of protein 
concentration, dialyzing buffer pH, salt concentration and renaturation temperature 
were designed to select an optimized set of conditions for both WT and DES Urzymes 
(Table 4, bold). However, while being dialyzed, the wild type TrpRS Urzyme showed 
signs of aggregation which led to the decision to further characterize only the 
redesigned construct. 
 
Table 4: Renaturation condition optimization for the TrpRS Urzymes. The 7th 
sample (blue) had highest relative specific activity.  
 
Pyrophosphate Exchange Assay Show Significant Activity for the Renatured 
TrpRS Urzyme 
The renatured Urzyme amino acid activation activity, as showed in the below 
table, is 105 times weaker than that of the native enzyme. In the table, the native 
TrpRS activity is normalized to 1 unit. It is interesting that the wild type Urzyme, 
besides being more insoluble, also has lower activity. This indicates that the 
 
Sample 
Protein 
concentration                                                  
aaa(OD280) 
pH of 
dialyzing
buffer 
[KCl] 
(mM)
 
Renaturation 
temp (oC) 
 
Relative 
specific 
activity 
1 2 8.6 50 25 8 
2 10 7.0 50 4 1 
3 6 5.4 250 4 2 
4 6 7.0 250 4 2 
5 10 5.4 50 25 2 
6 6 8.6 50 25 7 
7 2 8.6 50 4 9 
8 2 5.4 250 25 7 
9 2 7.0 250 4 3 
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redesigned Urzyme, a minimal catalytic domain (MCD), might have had more proper 
folding thus becoming more stable, soluble, and active.  
An active site mutant, D146A, showed 20 fold higher activity compared to the 
redesigned Urzyme. The same mutant introduced in the full length enzyme reduces 
the activity 200 fold. This suggests a different catalytic mechanism for the Urzyme. 
More importantly, it proves that the activity detected is coming from the Urzyme 
itself since a targeted mutation allows its modulation. 
    Table 5: Activity of the refolded TrpRS Urzymes – wild type (WT) and 
redesigned (DES) compared with the full length enzyme, native D146A mutant 
and ribozyme (Pham et al., 2007). 
 
For reference, the activity of an extensively modified ribozyme (Kumar and 
Yarus, 2001) was ~3 times slower than the redesigned Urzyme (Des MCD). 
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Figure 10: The TrpRS Urzymes, quantitated by immunoblotting and silver 
staining (b.), were used for pyrophosphate exchange assay. The noise level in (a., 
dotted green line) was subtracted as background to produce (c.) (Pham et al., 2007).   
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Discussion 
Rosetta Design and Choice of Mutations  
As indicated in the Materials and Methods section, the number of biological 
sequences scanned was limited to sixty for each linker. The TrpRS Urzymes 
synthesized have the lowest energy scores within the limit, however, might not be the 
best among all naturally occurring sequences in the database. It is notable that in all 
seven linkers ranging from 0 to 6 amino acids long, the zero length linker is shown to 
be most stable. This result might imply that the 5 Ångstrom gap between residues 
threonine 46 and glycine 121 could have once not existed, and thus, that the 
connecting peptide 1 would be a later insertion. The computational construction 
phase, however, only tries to design linkers using two short side chain amino acids, 
alanine and glycine, in a certain number (6) of all possible combinations. The 
rationale of using A and G is to avoid any interaction between the inserted side chain 
and the main backbone. Nevertheless, this brings more constraints to the optimization 
process. Another constraint is the number of residues adjacent to the side of T46 and 
G121 that are allowed to mutate. The Urzyme design, indicated to be stable in a 40 ns 
molecular dynamics experiment (H. Hu, data not showed), is still open for more 
improvement.  
Of all mutations predicted to stabilize and solubilize the TrpRS Urzyme, only five 
are from hydrophobic to hydrophilic (Table 3), which would directly change the 
interaction with solvent. It has been noticed that Rosetta Design has a tendency to 
place large patches of hydrophobic residues together (Liu and Kuhlman, 2006). Since 
a significant part of the surface area of the full length TrpRS has been removed, 
exposing the hydrophobic core, the introduction of more hydrophobic residues at 
different locations in the Urzyme might help recover the proper folding. However, the 
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drawback of this is that the designed molecule is more likely to aggregate. A more 
stable and soluble Urzyme could be the next target as the algorithm is being rapidly 
developed. 
Assaying Weak Amino Acid Activation Activity after Renaturation and tRNA 
Acylation Activity 
The plasmid carrying the TrpRS Urzyme was transformed into BL21 cells 
resulting in the over-expression of the desired protein. Over-expressed protein usually 
accounts for approximately 50% of the total protein. Since possessing a 105-fold 
weaker amino acid activation activity, the Urzyme may be toxic for the cells. 
Evidence that this is the case includes the fact that the plasmid is rapidly lost, even 
when selective pressure is maintained by using antibiotics. The presence of the 
majority of the Urzyme in the inclusion bodies is an indicator for aggregation. As 
previously predicted, the Urzyme activity would be much weaker, thus, could be 
easily interfered by the full length enzyme activity brought by the host cell. Since this 
contaminating activity comes from the soluble form that stays in the supernatant, 
purifying the molecule from the insoluble fraction does have an advantage in 
eliminating the host cell contaminating activity. However, the wild type Urzyme tends 
to go back to an aggregated form in the renaturation process. This phenomenon led to 
the decision to do further characterization extensively with the redesigned construct. 
Together with a molecular dynamics simulation done by a colleague, the higher 
tendency of redesigned Urzyme to stay in soluble fraction compared to the wild type 
confirms the success of Rosetta Design to stabilize and solubilize the Urzyme. 
Nevertheless, no structural analysis has been done beyond molecular dynamics to 
examine whether the refolding process is complete and accurate. A soluble form of 
TrpRS Urzyme is still preferable. It is important to notice the D146A active site 
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mutant, which reduces the reaction rate of the native enzyme by a factor of 200, 
surprisingly increases that of the redesigned Urzyme by a factor of 20. This result was 
unexpected, however, it indicates that the detected weak activity is not an artifact, and 
possibly, implies a different mechanism for the Urzyme.  
Since amino acid activation is the first half of the reaction that is not dependent on 
tRNA, a second assay for cognate tRNA acylation as described by Wolfson and 
Uhlenbeck is necessary (Wolfson and Uhlenbeck, 2002). TrpRS Urzyme lacks the 
connecting peptide 1 containing the tRNA interacting helix but still retains other 
elements thought to be part of the tRNA binding site (i.e. residues 142-150 of the αE 
helix) that could assist the second half of the aminoacylating reaction (Jia et al., 
2002). It will also be interesting to co-express the dissected domains, CP1 and CTD 
either in cis or in trans to unravel the role of those in catalysis.  
Implications for TrpRS Evolution 
The exclusive differences in structure and catalytic mechanism (e.g. tRNA 
acceptor stem binding mode, hydroxyl group specificity) described earlier strongly 
supports the idea of two separate ancestors for class I and class II aaRS. At first 
glance, the hypothesis proposed by Rodin and Ohno that the two classes might have 
originated from two complementary strands of one gene is very unusual. If that is the 
case, the deleterious (e.g. lethal or nonsense) mutations occur in one strand may lead 
to inactivation of the gene on the other strand. However, one might want both aaRS 
classes encoded in one DNA fragment because that would save the genetic material 
and more importantly, allow synchronized expression, especially in a pre-cellular 
environment. One of the very first pieces of evidence for the Rodin-Ohno hypothesis 
came from structural alignment analysis. The DNA encoding one class’s conserved 
motifs is used to generate a complementary strand, which is then computationally 
 37 
decoded into amino acid sequence. It is interesting that the resulting peptide showed 
non-random homology to the signature sequences of the other class (Rodin and Ohno, 
1995). 
Another important clue is the existence of additional functional domains among 
aaRSs. The two variable-length connecting peptides lying between two segments of 
the conserved Rossmann fold were once thought unrelated to the catalytic activity.  
However, the connecting peptide 1 (CP1) is now determined to be responsible for the 
proofreading (editing) activity of at least five aaRS. Connecting peptide 2 (CP2) in E. 
coli LeuRS, whose sequence is very similar to E. coli leucine-specific binding protein 
(Williamson and Oxender, 1990), is considered as a later insertion bringing more 
fidelity to the aminoacylation reaction (Zhou et al., 2008). 
In an article published in 2002, Carter and Duax have pointed out the homologies 
between a real sense/antisense coding system and the two aaRS classes. Class I and 
class II aaRS structurally resemble Achlya klebsiana glutamate dehydrogenase (GDH) 
and HSP70-like chaperonin (a heat shock protein), respectively (Carter and Duax, 
2002). The two latter proteins are shown to result from complementary strands of the 
same contemporary gene (LéJohn et al., 1994). This interesting observation has 
gathered controversial feedback. Williams et al. (2009) has recently argued about the 
accuracy of the methods used by the authors in order to deduce their conclusion. The 
TrpRS Urzyme model initiated in this chapter suggests a possibility that two classes 
were once encoded by one ancestral gene, and that later insertions were added to 
enhance the overall performance of aminoacylation. Hence, this is important evidence 
implicating aaRS sense/antisense origin, reinforcing Rodin-Ohno hypothesis (Rodin, 
Rodin and Carter, 2009). 
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Conclusion 
Solving the question of how two contemporary class I and class II aaRS might 
have emerged and evolved would shed light on the involvement of these enzymes in 
current pathways and probably allow the prediction of new functions. This chapter 
describes a TrpRS Urzyme constructed by fusing two discrete halves of the ATP 
binding Rossmann fold that shows significant amino acid activation activity. The 130-
residue long peptide, lacking the connecting peptide 1 and the carboxyl-terminal 
anticodon binding domain that make up 60% the mass of the active dimer, activates 
tryptophan with 105 times weaker activity. However, compared to non-catalyzed 
reaction on a logarithmic scale, it accelerates the rate by a factor of 109, and thus 
lowers the activation free energy by –12.4 Kcal/mol. The overall rate is accelerated by 
1014, and therefore lowers the activation energy by –19.24 Kcal/mol. The ratio of the 
Urzyme’s catalytic rate enhancement to that of the native enzyme in terms of 
activation free energy is therefore –12.4/-19.24 = 0.644 ~65%, and thus, is a very 
significant fraction of the overall rate enhancement of the native enzyme. It is 
important to know that this is not contaminating activity from the host cell TrpRS 
since the empty vector control has been substracted as background noise. Besides, 
TrpRS Urzyme has been purified through renaturation from the inclusion bodies, 
separately from the soluble fraction that could contain host-cell native form of the 
enzyme. Further experiments are to be done to characterize the Urzyme to understand 
the modular complementation of the removed domains. More importantly, this 
Urzyme might be a potential candidate for the ancestral class I aminoacyl-tRNA 
synthetase postulated in Rodin-Ohno hypothesis. The procedures described in this 
chapter can serve as a paradigm to construct a class II Urzyme to further verify the 
sense/antisense relationship hypothesized to be once existed.  
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YIELD OF TRPRS URZYME IN THE SOLUBLE FRACTION 
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Abstract 
The next step to verify the accuracy of protein design is expression and 
characterization of the expressed construct. As previously described, a redesigned 
tryptophanyl-tRNA synthetase Urzyme showed significant tryptophan activation 
activity, and when refolded, stayed in the soluble form, unlike the wild type which 
had a pronounced tendency to aggregate. However, the majority of the Urzyme was in 
the inclusion bodies and required renaturation, which might lead to improper folding. 
Using different expression systems, one often can bring the protein of interest to the 
soluble fraction with a highly soluble carrier protein. This chapter is devoted to 
determination of a suitable vector to solubilize the redesigned TrpRS Urzyme. Of the 
two systems described, pET SUMO (Small Ubiquitin-related Modifiers) (Novagen) 
increased the total yield but not the solubility. The other vector, pMAL-c2x encoding 
the Maltose Binding Protein (MBP) (New England Biolabs), improved the soluble 
yield substantially. More importantly, when digested with Factor Xa to remove the 
carrier protein MBP, the Urzyme was stable and showed tryptophan activation 
activity comparable to that of the original refolded Urzyme. Michaelis-Menten 
kinetics of this solubilized TrpRS Urzyme are described in Chapter 4. Further 
characterization remains a future direction. 
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Introduction 
Protein expression and purification are essential for further manipulations in 
biochemical research. The need for having large amounts of protein synthesized and 
purified has led to the development of different expression systems, efficient 
purification kits and a large database for yield, purity optimization methods as well as 
troubleshooting tips. It has been thoroughly discussed in the book of Current 
Protocols in Molecular Biology (Wiley Interscience, 1991) about the most widely 
used expression systems. Among those, Escherichia coli has become an extremely 
popular host with a certain number of advantages compared to the others.  
E. coli expression systems can be controlled at both transcriptional and 
translational levels. With different mutations at the origin of replication, one is 
capable of manipulating the speed of bacterial growth and thus, expression. It has 
been suggested that low plasmid copy number would be appropriate for desired 
proteins that are potentially toxic for the cell. For that purpose, pET, with a copy 
number ranging from 15 to 20 per cell, is appropriate. As discussed in the previous 
chapter, the TrpRS Urzymes have been subcloned into pET42a (+) vector, which 
would solve the aggregation problem of the Urzyme, suggested by the fact that the 
plasmids are lost quickly, in contrast to the wild-type TrpRS-coding plasmid. Further 
expression in a tightly controlled system, BL21 pLysS provides additional protection 
against toxicity.   
Once efficiently expressed, a protein can be in either soluble form in the 
supernatant fraction or denatured state in pellet fraction that includes the inclusion 
bodies. Purifying proteins from inclusion bodies through renaturation after an initial 
denaturing step to solubilize the pellet fraction by urea or guanidium hydrochloride 
has been described by many groups. However, additional complicated procedures 
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have become necessary to assure proper folding of the protein of interest after 
renaturation. Attention to folding is necessary especially if the protein has a marginal 
stable structure and catalytic activity. This concern gives rise to methods of using a 
highly soluble tag, conjugated to the molecule as fusions. A variety of carrier proteins 
with different sizes are available for consideration, including maltose binding protein 
(MBP), glutathione-S-transferase (GST), and small ubiquitin-related modifiers 
(SUMO). Beside the effect of shifting the expression of the previously insoluble 
desired protein into the soluble fraction, one might benefit from using the carrier for 
further purification steps. Resins conjugated with substances that have high affinity 
for carrier proteins have become commercially available, as well as the necessary 
proteases to separate the target from its carrier.  
The phenomenon described with the wild type TrpRS Urzyme in the refolding 
process (Chapter 2) implies its low solubility and high tendency to aggregate. Besides 
paying necessary routine attention to internal cleavage sites by the recommended 
proteases used to digest the carrier-ORF linker, there is a possibility that the Urzymes 
may aggregate and go back to the insoluble fraction without the presence of the 
carrier. This will lead to the potential loss of activity, hence, requires special 
considerations when selecting a fusion system. 
Maltose binding protein fusion is synthesized from the pMAL plasmid (Figure 
11). New England Biolabs has two main sub-systems to express the protein of interest 
either in the cytoplasm or periplasm. The depicted pMAL-c2 plasmid belongs to the 
former sub-system, which would utilize Factor Xa to cleave off the maltose binding 
protein moiety. The protease’s recognition site is Ile-Glu-Gly-Arg (IEGR). 
Figure 12 is an illustration of glutathione-S transferase fusion system developed 
by GE Healthcare and Life Sciences. The pGEX plasmid contains a cleavage site for 
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the Tobacco Etch Virus (TEV) protease, whose recognition sequence (ENLYFQG is 
the most commonly used, with some variations at non-critical positions) is longer than 
that of Factor Xa. As a result, this system is preferred for reducing non-specific 
internal cleavage. 
SUMO is an expression system recently developed to serve the purpose of 
solubilizing proteins known to be difficult when it comes to expression in soluble 
fraction (Figure 13). The summary of most commonly used carrier proteins in Table 6 
indicates that SUMO tag has average size compared to others. Membrane proteins, for 
example, have proved to be successfully expressed and purified in SUMO conjugated 
form (Marblestone et al., 2006). The authors also point out that SUMO protease is 
much more efficient than TEV protease. The former binds it substrate with a higher 
affinity and is a faster catalyst. Collectively, the SUMO system has become the first 
choice to solubilize and purify protein efficiently. 
The TrpRS Urzyme has been improved for solubility and stability by Rosetta 
algorithms as indicated in the previous chapter. Molecular dynamics experiment have 
shown that the structure is stable; however, when expressed in the low copy number 
plasmid pET42, the wild type Urzyme aggregated in urea dialyzing buffer even in the 
presence of substrates (ATP and tryptophan). Since the predicted activity of TrpRS 
Urzymes is much weaker than the full length enzyme, a high yield is crucial for better 
detection of activity. However, use of many purification steps reduces the yield to the 
point where it is not satisfactory. Refolding poses another problem, which is the 
unknown efficiency of renaturation process. In other words, it would become 
necessary to determine what percentage of the Urzyme is properly refolded. To avoid 
further complication with the TrpRS Urzyme constructs, the open reading frame has 
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been subcloned into different expression vectors known to increase the fraction of the 
desired protein in stable and soluble form.  
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Figure 11: pMAL-c2x expression vector (New England Biolabs) uses the maltose 
binding protein (MBP or MAL) as the carrier protein. 
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Figure 12: GST is one of the most popular systems used for protein 
expression and purification. The pGEX plasmid (GE Healthcare & Life Sciences) 
includes glutathione-S transferase gene whose product assists in affinity purification 
(Harper and Speicher, 2008). 
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Figure 13: pET SUMO system from Novagen showing the SUMO carrier 
protein at the N-terminal of the open reading frame (Manufacturer’s 
manual). 
 49 
 
 
 
 
 
 
 
Figure 14: Comparison expression levels in soluble and insoluble fractions with 
different carrier proteins to solubilize difficult-to-express proteins (Marblestone 
et al., 2006).   
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Table 6: Carrier proteins frequently used to assist solubility and affinity 
purification (Marblestone et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table1.Sequence and size of tags 
   
 Size 
 Tag  Residues  Cleavage site  (kDa) 
 Poly-His  6  —  0.84 
 Ubiquitin  76  ENLYFQ’GXX  8 
 SUMO  100  GG’XXX  11.5a 
 MaltoseBindingprotein  396  ENLYFQ’GXX  40 
 GlutathioneS-transferase  211  ENLYFQ’GXX  26 
 Thioredoxin  109  ENLYFQ’GXX  12 
 NUSA  495  ENLYFQ’GXX  55 
 a   SUMO migrates aberrantly at 20kDa in an SDS–polyacrylamide gel. 
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Materials and Methods 
Subcloning from an Original Vector to the Target Plasmid 
Restriction enzymes and other molecular biology reagents were obtained from 
New England Biolabs and were used according to the manufacturer's protocols. 
Forward and reverse primers for PCR amplification were designed to be 
complementary to the Urzyme sequence, containing extra nucleotides coding for N-
terminal FLAG tag and C-terminal 6xHIS tag. Desired restriction sites were also 
introduced in the primer design step. Following digestion with the appropriate 
restriction enzymes, the PCR products were cloned to E.coli expression plasmids pET 
SUMO (Novagen) or pMAL-c2x (NEB) for use in bacterial strain BL21(DE3)pLysS 
(Novagen). All constructs were confirmed by DNA sequencing. 
Protein Expression 
All TrpRS fragments were expressed directly after transforming with plasmid 
DNA. After transformation, 100 µl competent cells were incubated in 1ml LB media 
at 37°C for 1 hr with shaking and then used to inoculate 100 ml growth media (LB 
plus 2% glucose, appropriate antibiotics at 30 µg/ml for kanamycin, 34 µg/ml for 
chloramphenicol, 100 µg/ml for ampicillin). The inoculum was shaken at 250 rpm 
overnight at 37°C and then transferred to 1 l fresh LB with the same antibiotics 
concentrations. At OD600 = 0.4–0.8, isopropyl-β-D-thiogalactopyranoside (IPTG) was 
added to 0.3 or 1 mM final concentration to induce gene expression. Harvest began 3 
or 14 hr after induction. 
Analysis of Fragments from Supernatant and Inclusion Bodies 
A cell-free extract was prepared from frozen cell pellets by lysing cells in 50 mM 
Tris, 10% sucrose (pH 7.5), using sonication in pulse mode (3x15 seconds) combined 
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with a continuous flow pressure cell (Avestin) when indicated, followed by 
centrifugation at 14,000 rpm for 30 min at 4°C. 
Quantitation of Soluble Yield in the Supernatant Compared with Insoluble 
Fraction in the Inclusion Bodies 
Both immunoblotting with anti-FLAG antibody and Coomassie Blue staining 
were used for estimating protein concentration. As the silver-stained gels showed that 
the samples were quite pure, we determined most concentrations by using Coomassie 
Blue staining combined with the absorbance obtained from a Nanodrop 
spectrophotometer.  
Factor Xa Cleavage 
The MBP fusion was digested with Factor Xa (NEB) overnight at 4°C with 
rotating. The ratio of substrate and enzyme is 1:50 (w/w). Concentrate fusion was 
diluted to a final concentration of 10% glycerol from stock stored in 50% glycerol 
(1:5 dilution). The digestion mixture was used directly for tryptophan activation 
assay.   
32PPi Exchange Assays for Tryptophan Activation 
Samples were assayed using the traditional 32P-pyrophosphate exchange as 
described (Joseph and Muench, 1971) except that a 3-fold reduction of background 
32P counts was achieved by collecting the charcoal containing labeled ATP on 
disposable spin columns, washing, and eluting the bound ATP with 50 µl of pyridine 
at 37°C. 
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Results 
The SUMO Expression System Improved the Yield but Not the Solubility 
As shown in Figure 14A, in the original pET42 a system, most of the protein was 
in the inclusion bodies pellet (P). Subcloning to pET SUMO vector improved the 
expression level (Fig. 14B) but the SUMO fusion stayed insoluble in the pellet (P). 
The size of SUMO-fused redesigned Urzyme was at the expected position of 
approximately 25 kDa. TrpRS Urzyme accounted for 56% of the fusions which 
suggested that the 11 kDa SUMO carrier did not have a sufficiently large molecular 
weight to assist proper folding for solubility of the Urzyme. A more powerful carrier, 
involving a bigger carrier protein was desired after this first vector failed to solubilize 
the Urzyme. MBP became a reasonable candidate for the next step. 
The Majority of MBP Fusion Protein was in the Soluble Fraction 
The simplified linearlized pMAL-c2 x map used for subcloning is shown in Figure 
16A below. MBP (blue) was approximately three times bigger than the subcloned 
open reading frame of TrpRS Urzyme (ORF, green). The construct was doubly tagged 
with N-terminal FLAG and C-terminal 6xHIS. The soluble (S) and insoluble (P) 
fractions immunoblotted with anti-FLAG antibody showed the majority (80%) of the 
fusion in the supernatant (Fig. 16B). Amylose resins gave pure, soluble fusion after 
affinity column (Figure 17). However, the fusion was inactive in the initial tryptophan 
activation assay (data not shown). 
Factor Xa Cleavage Released Tryptophan Activation Activity 
To verify the possibility that maltose binding protein, the three times bigger 
carrier, might interfere with the activity of the smaller TrpRS Urzyme, perhaps by 
covering its active site, we used Factor Xa according to the manufacturer’s manual. 
Factor Xa, a protease whose recognition site was embedded in between MBP and the 
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             M       NI        S             P                         M      NI       S             P          
                                    A                                                         B 
Figure 15: SUMO expression system increases the total Urzyme production but 
not the solubility (Coomassie Blue stained SDS-PAGE gels). A: redesigned TrpRS 
Urzyme. B: SUMO fusion. M: molecular weight marker. NI: non-induced control. S: 
supernatant. P: pellet (Pham, unpublished). 
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                                                                A                                    
                                                                                                      
                                                         S           P 
                                                                B 
Figure 16: MBP expression system kept the TrpRS Urzyme in the supernatant. 
A: MBP fusion map with indicated relative positions of the maltose binding protein 
gene, protease cleavage site, affinity tags and the open reading frame. B: anti-FLAG 
immunoblotted samples from the soluble (S) and insoluble (P) fractions (Pham, 
unpublished data).  
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Figure 17: Expression and purification of maltose binding protein-fused 
redesigned TrpRS Urzyme. M: molecular weight marker. NI: non-induced control. I: 
induced expression, total fraction. S: induced expression, soluble fraction. FT: flow 
through fraction from amylose column. W: first washing fraction after FT. E1-6: 
elution fractions. Ec: concentrated fusion (Pham, unpublished). 
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Figure 18: Factor Xa cleavage released the active TrpRS redesigned Urzyme 
while the same protease did not produce extra digestion products for the empty 
vector control. M: Molecular weight marker. E: empty pMAL-c2 control. Ec: E 
cleaved with Factor Xa. F: fusion protein. Fc: F digested with Factor Xa. N: native 
TrpRS (Pham, unpublished data).  
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ORF (Fig. 16), was added to digest the fusion protein. As shown in Figure 18 above, 
the empty vector control (pMAL-c2) (E) was not digested by the protease (Ec) 
whereas after cleavage, the fusion (F) released the MBP and the Urzyme (Fc). The 
native full length TrpRS was run in the last lane (N).  
The digestion mixture was directly used for pyrophosphate exchange assay. 
Preliminary results showed that the released Urzyme fragment was active (data not 
shown). 
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Discussion 
The pET SUMO Expression System did not Solubilize TrpRS Redesigned Urzyme 
Marblestone et al. (2006) have shown that pET SUMO is powerful in solubilizing 
proteins which are known to be difficult to express. Besides, the protease used in this 
system is preferable since it has higher affinity to the substrate and is more active. 
However, the SUMO-TrpRS Urzyme fusion cannot be successfully expressed in 
soluble form. The yield is substantially higher but most of the protein aggregates to 
form inclusion bodies. It is notable that this aggregation also occurs when induction is 
performed at 18 or 25oC. Under these conditions, E. coli does not form inclusion 
bodies, but the SUMO-TrpRS Urzyme construct is still in the insoluble fraction. It is 
important to note that the SUMO carrier protein is smaller than the attached TrpRS 
Urzyme. This phenomenon might indicate that a larger carrier protein is desired to 
solubilize the highly insoluble redesigned fragment, or, in other words, the SUMO has 
been overloaded. It is likely that a system working for some proteins will not work for 
others. Hence, subcloning to a different expression vector is rationalized.  
Considerations for Expressing an Enzyme as a Fusion Protein 
Since the SUMO fusion seemed to be insufficient to shift the expression into 
soluble fraction, we tried expression in the pMAL-c2x vector that encodes the maltose 
binding protein, which is three times bigger than TrpRS Urzyme. This system has 
successfully solubilized the construct. However, this construct also conceals the 
Urzyme’s activity. A significantly reduced tryptophan activation activity was detected 
for the fusion form. The observed activity was only 5% compared to that of the 
cleaved fusion protein preparation. 
Yet, when digested with the protease Factor Xa to remove the fused carrier 
protein, the activity was recovered. This result could be an implication for the 
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interference of the maltose binding protein with TrpRS Urzyme active site. With a 
mass three times the size of the Urzyme, it is possible that MBP would make 
unexpected interactions with residues critical for catalysis. Besides, the carrier might 
have blocked access of substrates to their binding sites. Hence, the ratio between the 
sizes of carrier protein and the protein of interest requires considerations, especially 
when an enzyme is to be attached.  
Solved and Remaining Problems 
With the implementation of pMAL-c2 expression system, I have successfully 
solubilized the redesigned TrpRS Urzyme. As previously discussed, the pET42a (+) 
plasmid carrying TrpRS Urzymes tends to be unstable and lost after some bacterial 
division cycles, implying possible toxicity. Thus, this soluble fusion form has an 
advantage over expressing the Urzyme itself regarding the maintenance of the 
plasmid. Furthermore, the problem of aggregation can be also reduced as long as the 
Urzyme is fused with the maltose binding protein carrier which probably will increase 
the storage time of purified material in 50% glycerol at -20oC. The fact that the 
activity is released after Factor Xa cleavage may be another advantage considering 
MBP a protecting cage that helps preserve the Urzyme. This protecting role was 
verified by a digestion experiment done with time, temperature and glycerol 
concentration as variables in which aggregation was observed after longer incubation 
time, at higher temperature or without glycerol (data not showed). 
It is important to note that the cleavage reaction mixture is used directly for 
pyrophosphate exchange assay. This condition might interfere with the activity of the 
Urzyme, since there are remaining reactants and unwanted products (i.e. fusion 
protein, protease, MBP). Further manipulation is necessary to purify the TrpRS 
Urzyme after cleavage. However, as noted next, several failures to produce activity 
 61 
after cleavage of the fusion protein confirm that none of these contaminants has 
competing activity.  
A different problem recently identified is that a second lot of Factor Xa (NEB) 
seems to produce intriguing cleavage pattern with extra bands (data not shown), and 
failure to reproduce tryptophan activation activity. This could be a sign for non-
specific internal cleavage since there is no Ile-Glu-Gly-Arg sequence (the protease’s 
canonical recognition site) in the TrpRS Urzyme. Investigation is to be done to 
explain, and hopefully solve, this remaining problem. 
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Conclusion 
Of the two expression systems used to solubilize the redesigned TrpRS Urzyme, 
pET SUMO produced substantial amount total protein compared to the original 
pET42a; however, it was not successful in keeping the construct in the supernatant 
fraction. A higher molecular weight carrier protein, MBP, was chosen to provide 
stronger solubilizing force. MBP-fused Urzyme was soluble but did not have expected 
tryptophan activation activity. Factor Xa, the protease used to separate the carrier 
protein MBP and the protein of interest, released the Urzyme fragment which showed 
activity in the pyrophosphate exchange assay. Further characterization of catalysis by 
this Urzyme will help unravel the role of the missing domains, and is discussed in 
Chapter 4. 
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CHAPTER 4 
 
TRYPTOPHANYL-TRNA SYNTHETASE URZYME SHOWS COMPARABLE 
AFFINITY FOR ATP BUT A 103-FOLD HIGHER
 
KM FOR TRYPTOPHAN IN 
AMINO ACID ACTIVATION, INDICATING A POTENTIAL ROLE FOR THE 
CONNECTING PEPTIDE (CP1) IN AMINO ACID BINDING POCKET 
STABILIZATION AND AMINO ACID SPECIFICITY 
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Abstract 
A stable and soluble tryptophanyl-tRNA Urzyme has been expressed in the fusion 
form with maltose binding protein in the pMAL-c2x vector system. This Urzyme is 
the result of a computational design phase in which the connecting peptide 1 and the 
C-terminal domain were removed. 17 mutations were introduced in the construction 
to stabilize and solubilize the Urzyme. The preliminary results show significant 
tryptophan activation activity for this 130-residue long peptide. In this chapter, 
Michaelis-Menten kinetics parameters for the TrpRS Urzyme obtained from 32PPi 
phosphate exchange assay will be discussed. Compared to the full length enzyme, 
TrpRS Urzyme binds ATP with similar affinity; however, tryptophan binding is 
approximately 103 times weaker. This result argues that either the removed CP1 and 
CTD domains, or both, contribute in important ways to amino acid specificity. 
Furthermore, since the TrpRS CP1 insertion occurs at the same position as the editing 
domain of five other aaRSs, this finding is important evidence supporting the 
conclusion that the CP1 fragment has always served to enhance the amino acid 
specificity of Class I aaRS. CP1 therefore appears to be the potential birthplace for 
editing activity, which would also support the hypothesis of later internal insertion to 
a primitive polypeptide (Rodin and Ohno, 1995; Pham et al., 2007).  
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Introduction 
AaRSs very likely evolved from a simpler, more primitive polypeptide chain into 
complex multi-domain, multi-function contemporary enzymes with enhanced 
catalytic activity and fidelity. They have been shown to participate in various 
biological processes. Structural analyses indicate that both class I and class II aaRSs 
contain small (~120 amino acids) catalytic cores (Rodin and Ohno, 1995). 
Complementing these cores, there are internal and external insertions, some well 
characterized structurally and functionally, the others still under investigation. For 
instance, the N-terminal extension of mammalian TrpRS is subjected to proteolysis, 
producing natural mini TrpRS variants shown to have antiangiogenic/cytokine 
activity. The carboxyl-terminal domain of aaRS interacts with the anticodon, which is 
important for RNA recognition and binding affinity. More interestingly, a domain 
called connecting peptide 1, which varies in size and in five aaRSs, is shown to be the 
originating location of editing activity that amplifies the fidelity of aminoacylation in 
those cases involving similar naturally occurring amino acids.  
There are two proposed mechanisms for aaRS editing: pre-transfer in which the 
non-cognate adenylate is hydrolyzed and post transfer that works on clearing mis-
acylated tRNA through hydrolysis (Schimmel and Schmitdt, 1995). Each mechanism 
has distinct features and varies from one aaRS to another. Since pre-transfer editing 
occurs in the first half of the two-step aminoacylation reaction, tRNA might not be 
required for the removal of mis-activated amino acids. However, for some aaRSs, e.g. 
LeuRS, it has been shown that the canonical core and CP1 both contribute to the 
proofreading activity (Boniecki et al., 2008; Zhou et al., 2008). Homologs of CP1 
have been found to express editing activity in a number of organisms. The in trans co-
existence of ProX and YbaK with bacterial ProRS and CysRS, respectively, enhances 
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the fidelity of aminoacylation (Ahel et al., 2003; An and Musier-Forsyth, 2005). At 
first glance, these isolated domains seem to be redundant. However, this editing 
activity provided from a different protein might be a primitive mechanism before 
domain fusion to the catalytic core brought the non-cognate substrates into closer 
proximity to the editing site.  
Evidence for evolution at the molecular level has been well documented for a 
number of enzymes. A frequently observed and proved mechanism in this process is 
gene duplication followed by domain fusion or insertion (Traut, 2008). TrpRS CP1 is 
only 74-residue long and the native full length enzyme does not have editing activity. 
However, it is an ideal system to study since it is the smallest aaRS and the gap 
between the two free ends resulted from CP1 removal is only 5 Ångstrom long, which 
can be joined by a short linker combined with relaxed adjacent backbone. A molecule 
of approximately 120-130 residues in length like TrpRS Urzyme might be a potential 
candidate for the ancestral class I aaRS. Under this hypothesis, other additional 
domains were later insertions and fusions to the primordial genes. The activity of 
TrpRS Urzyme previously described in Chapter 2 (published as Pham et al., 2007) 
supports this paradigm. However, further characterization is necessary to determine 
the detailed mechanism and explore the role of the removed domains CP1 and CTD.  
The idea of ancestral gene resurrection has been implemented by several groups to 
study evolution at the molecular level. One of the most striking results comes from 
the work on the steroid hormone receptors (Thornton and Bridgham, 2007). In 
Chapter 16 of the book Ancestral Sequence Reconstruction, the authors have 
described their mutational analysis with the contemporary protein. By making 
multiple point mutations, they were able to modulate the specificity of the receptor for 
different ligands. Combined with the divergence of ligand specificity along the 
 68 
 
phylogenetic tree, the group has built a detailed pathway for the receptor evolution, 
further indicating that some of the evolutionary events were irreversible (Bridgham, 
Ortlund and Thornton, 2009).  This TrpRS Urzyme construction, pursuing the same 
target of ancestral gene resurrection to study the recapitulation of putative 
evolutionary events, is extremely challenging because it entails removal of whole 
structural domains to create a model for the ancestral enzyme, whose activity can be 
measured. On this system, changes can be made that might have occurred along the 
evolution leading to the contemporary enzyme. It is especially important that the 
effects of those changes can also be measured. In contrast to ancestral gene 
resurrection, however, amino acid changes in the conserved domains cannot be 
identified from a phylogenetic sequence analysis; we use biophysical chemistry from 
protein design to approximate putative sequence changes (Pham et al., 2007). 
A common steady state measurement used to study enzyme kinetics is the 
Michaelis-Menten experiment. Proposed in 1913 by the two scientists that this 
method is named after, Michaelis-Menten equation has been a standard representation 
of the relationship between an enzyme and its substrate (Michaelis and Menten, 
1913).  
v = vmax [S]/( Km + [S])  (I) 
                                            such that vmax = kcat [Eo] (II) 
Fitting the concentration-dependent activity data to equation (I) is used to 
determine two parameters: the maximum velocity vmax and the binding constant Km 
which are critical to understand the kinetics of any enzyme. From the main equation, 
the apparent second-order rate constant (the ratio of kcat over Km) of the enzyme can 
also be determined. Use of this parameter is a widespread indicator for enzymatic 
proficiency. Another assay to be considered is active site titration (Fersht, 1999) to 
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determine the active proportion of the total enzyme used; active-site titration is 
essential for accurate determinations of kcat because of relation (II). We have not yet 
performed active-site titration on the TrpRS Urzyme.  This chapter will be devoted to 
preliminarily study the Michaelis-Menten kinetics of tryptophan activation, which is 
the first half of the reaction catalyzed by the full length TrpRS enzyme. 
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Materials and Methods 
Expression and purification of MBP fusion  
MBP-TrpRS Urzyme fusion was expressed directly after transforming with 
plasmid DNA. After transformation, 100 µl competent cells were incubated in 1ml LB 
media at 37°C for 1 hr with shaking and then used to inoculate 100 ml growth media 
(LB plus 2% glucose, 100 mg/ml for ampicillin). The inoculum was shaken at 
250 rpm overnight at 37°C and then transferred to 1 l fresh LB with 100 mg/ml 
ampicillin. At OD600 = 0.4–0.6, isopropyl-β-D-thiogalactopyranoside (IPTG) was 
added to 0.3 mM final concentration to induce gene expression. Harvest began 3 hr 
after induction. 
Cells were collected by centrifugation at 4,500 rpm for 20 min at 4°C, and then 
resuspended in lysis buffer (50 mM Tris, 10% sucrose, pH 7.5). After overnight 
storage at -80°C, the cells were thawed on ice and lysed by sonication (3x15 sec). The 
lysate was centrifuged to separate the supernatant fraction from the inclusion bodies at 
14,000 rpm for 30 min at 4°C. The supernatant from this step was diluted 1:5 with the 
amylose resin High Flow (NEB) column buffer (20 mM Tris-HCl, 0.2 M NaCl ,1 mM 
EDTA,10 mM beta-mercaptoethanol, pH 7.4) before loading onto a calibrated Biorad 
disposable column contained 2 ml of amylose-conjugated resin suspension for each 
10 ml of the diluted supernatant. The column was equilibrated with 3 column volumes 
(c.v.) of column buffer and the resin was washed with 5 c.v. The flow-through 
fraction was collected then the resin was washed with 8 c.v. of column buffer to 
minimize non-specific binding. The bound fusion protein was eluted in 1.5 ml 
fractions with elution buffer (column buffer plus 10 mM maltose). The first five 
fractions were combined and dialyzed overnight against 3x10 volumes of 50% 
glycerol dialyzing buffer (20 mM Tris-HCl, 50 mM KCl, 0.1 mM PMSF, 10 mM 
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beta-mercaptoethanol, 50% glycerol, pH 7.5) at 4°C. Samples were stored at -20°C 
after dialysis. An example of the purity of this preparation is shown in Chapter 3, 
Figure 17. 
Factor Xa Cleavage 
The MBP fusion was digested with Factor Xa (NEB) overnight at 4°C with 
rotating. The ratio of substrate to enzyme is 1:50 (w/w). Concentrated fusion protein 
was diluted to a final concentration of 10% glycerol from the stock solution stored in 
50% glycerol (1:5 dilution). The digestion mixture was used directly for the 
Michaelis-Menten tryptophan activation assays.   
ATP- and tryptophan- dependent 32PPi Exchange Assays for Tryptophan 
Activation 
Samples were assayed using the traditional 32P-pyrophosphate exchange as 
described (Joseph and Muench, 1971) except that a 3-fold reduction of background 
32P counts was achieved by collecting the charcoal containing labeled ATP on 
disposable spin columns, washing, and eluting the bound ATP with 50 µl of pyridine 
at 37°C. ATP and tryptophan were first depleted from the assay buffer in order to 
determine Michaelis-Menten constants as ATP- and tryptophan- dependent 
parameters, respectively. Stocks of ATP and tryptophan were added to the depleted 
buffer at indicated ranges of concentrations. Activity measurements collected were 
plotted against substrate concentrations. 
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Results 
TrpRS Urzyme Tryptophan Activation Activity is Dependent on ATP 
 
The kcat/Km previously obtained from refolded, redesigned TrpRS Urzyme 
expressed in pET42a plasmid was 105 times weaker than that of the full length 
enzyme. Digestion with Factor Xa recovered a cryptic tryptophan activation activity 
in the fusion protein. As described in the Methods section, to characterize ATP-
dependent Michaelis-Menten kinetics, ATP concentrations ranging from 0 up to 2 
mM were prepared. In order to compare such widely different enzymatic activities, 
the ratio v/vmax values were plotted against ATP concentration (Fig. 19). There was no 
activity when ATP was absent (concentration = 0 mM). As the ATP concentration 
increased, as shown in Figure 18 below, the kinetics of tryptophan activation of the 
native full length enzyme (dark blue diamond) was similar to that of the redesigned 
Urzyme (magenta square). They both showed typical hyperbolic saturation curves 
with vmax being approached at ATP concentration of approximately 2 mM.  
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Figure 19: ATP dependence of TrpRS and TrpRS Urzyme (MCD – minimal 
catalytic domain) in rate acceleration of tryptophan activation (Pham, 
unpublished). 
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Tryptophan Dependent Activity Assay 
A similar experiment was done to determine the tryptophan dependence of TrpRS 
Urzyme in tryptophan activation. As expected, when tryptophan was absent, there 
also was no activity detected. However, the Urzyme became more active as more 
tryptophan was added to the assay buffer. The saturation curve was not yet completely 
observed at 4 mM of the cognate amino acid substrate (Fig. 20A). On the other hand, 
the full length TrpRS reached maximum velocity rather early within the experimental 
tryptophan concentration range (Fig. 20B, orange line). When v/vmax ratios were 
plotted as before against different tryptophan concentrations used to titrate the 
Urzyme activity, the curve was essentially vertical. The behavior observed for the 
TrpRS Urzyme indicates a quantitatively different, and impaired tryptophan binding 
affinity for the TrpRS Urzyme which we verified by fitting the observed data to 
obtain Michaelis-Menten constants shown in Figure 20 and Table 7. 
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     A 
                  
 
                                                                   
                                                                      B  
                                                            
Figure 20: Full length enzyme and the Urzyme activate tryptophan differently. 
A:  Normalized tryptophan activation by the redesigned TrpRS Urzyme. B: 
Normalized tryptophan-dependent rate acceleration by full length enzyme (red) and 
Urzyme (blue) (Pham, unpublished). 
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TrpRS Urzyme has Comparable ATP Binding Affinity but Approximately 103 
Times Weaker Trp Binding Affinity Compared to the Full Length Enzyme 
The Michaelis-Menten constants obtained are summarized in Table 7 below. 
Compared to the native TrpRS, the Urzyme bound ATP equally tightly with a Km of 
0.68 mM. Rate acceleration was substantially lower which was consistent with 
previously determined activity for the renatured Urzyme. Interestingly, tryptophan 
binding affinity of the construct was greatly reduced. The Km value for tryptophan 
was approximately 1000 times higher (Table 7, bold), which indicated that the 
Urzyme might not be specific for its cognate substrate.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 7: Michaelis-Menten parameters determined for full length TrpRS and the 
redesigned TrpRS Urzyme (Pham, unpublished). 
 
 
 
 
 
 
 
 
2.38 0.00027 Km for Trp (mM) 
0.0001 0.054 Vmax (ATP) 
0.0001 0.034 Vmax (Trp) 
0.70 0.68 Km for ATP (mM) 
TrpRS Urzyme Full length  
TrpRS 
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Discussion 
TrpRS Urzyme Binds ATP with Affinity Comparable to the Full Length Enzyme 
The TrpRS Urzyme is designed by fusing the two discrete halves of the ATP-
binding Rossmann fold. Its ATP binding site composed of the TIGN and KMSKS 
signature loops is retained in the in silico construction phase. Hence, binding affinity 
to ATP is expected. However, the fact that this severely truncated peptide binds ATP 
as tight as the full length enzyme is striking. It is interesting that a TrpRS 46-mer 
peptide constructed from the first 46 amino acids of TrpRS containing only TIGN 
loop binds ATP even more tightly (L. Li, V. Weinreb, unpublished data). Since 
binding to ATP is the first step of the aminoacylation reaction, this feature is 
important to be further characterized. More interestingly, there is evidence showing 
that high concentration of ATP eventually destabilizes the full length enzyme (Carter, 
data not published). This behavior has not been tested with the Urzyme. Furthermore, 
the widely accepted Km value for ATP of the native TrpRS is 0.4 mM which is lower 
than the apparent value of approximately 0.7 mM discussed earlier in this chapter 
(Table 7). It is likely that the enzyme used in the assay was more active. Nevertheless, 
future assays are necessary to verify the difference.  
Binding Affinity toTtryptophan is Approximately 1000 Times Weaker 
The dramatic difference between the TrpRS Urzyme and full-length TrpRS is the 
weaker binding of tryptophan by the Urzyme. As shown in Table 10, whereas the 
ATP binding affinity remains essentially unchanged, the tryptophan affinity is 
approximately 103-fold different. The interpretation of this is that the redesigned 
Urzyme is unable to bind tryptophan efficiently. This result is unexpected considering 
the fact that the tryptophan binding pocket is preserved like the ATP binding site. 
However, a likely possibility is that some long-range interactions might have been 
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eliminated by removing the connecting peptide 1 and the carboxyl-terminal anticodon 
binding domain. This significantly reduced affinity could implicate a potential role 
for the connecting peptide 1 in amino acid recognition (Fig. 21 below). 
Evolution from a Primitive Polypeptide by Acquiring Functional Domain through 
Gene Fusion and Insertion Supports Rodin-Ohno Hypothesis  
Fig. 21 represents the resurrected connecting peptide 1 in a relative position to the 
redesigned TrpRS Urzyme. As previously mentioned in the introduction of this 
chapter, the TrpRS CP1 insertion is small and the native TrpRS does not have editing 
activity; nevertheless, at the same location has grown a bigger, structured domain 
capable of clearing mis-aminoacylated products in four other aaRSs (MetRS, LeuRS, 
IleRS, ValRS). More interestingly, the gap between TrpRS residues T46 and G121 
after its CP1 removal is only 5 Ångstrom long, indicating a possibility for ancestral 
direct linkage. It can be seen from the above figure that CP1 surrounds the tryptophan 
binding pocket. The insertion may work as an exo-skeleton to form and stabilize the 
proper configuration necessary for tryptophan recognition and binding.  
These results suggest a rather unexpected view of the ancestral TrpRS Urzyme, in 
which ATP bound tightly but tryptophan had only modest affinity. More importantly, 
the resutls bring the implications of low amino acid specificity into the discussion.  It 
is interesting to note that contemporary TrpRS is very specific for its cognate amino 
acid substrate, tryptophan. Praetorius-Ibba et al. (2000) made several mutations 
within the tryptophan binding pocket in an effort to switch its specificity to tyrosine. 
However, their conclusion confirms the failure to modulate amino acid specificity for 
this class Ic aaRS, indicating a possibility for the contribution of longer range 
interactions in defining the tryptophan binding pocket.  
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Recently, similar attemps to change GlnRS binding specificity from glutamine to 
glutamate have confirmed the importance of longer range interactions in configuring 
the amino acid binding pocket (Bullock et al., 2008). The authors show that 
introduction of Glu primary binding sites only into GlnRS is insufficient for the 
specificity switch. However, additions of two more engineered loops and one deletion 
drastically increase the generation of misacylated Glu-tRNAGln by GlnRS with 16,000 
fold difference. Interestingly, further investigation of the glutamine binding pocket 
reveals unusual interactions of the amino acid with ATP, the second substrate in the 
first step of the aminoacylation reaction (Corigliano and Perona, 2009). These studies 
on the class Ib GlnRS strongly support the existence of distal interactions outside of 
the tryptophan binding pocket in TrpRS, possibly originating from the CP1 domain.  
Early proteins were probably non-specific molten globules and hence we might 
expect that a non-specific type I aaRS would have had a selective advantage because 
it could generate a larger number of potentially functional variants. Only later, as the 
genetic code became firmly established, and globular proteins became more specific, 
would it have been necessary to evolve higher amino acid specificity. Multiple events 
of duplication, fusion, and insertion probably brought the additional domains assisting 
the primitive enzyme in substrate affinity and fidelity enhancements. The result of this 
postulated divergent evolution is the twenty contemporary aaRSs which are 
remarkably different, regarding both structure and mechanism. However, it was 
certainly essential for any imaginable protein synthesis machinery that ATP be bound 
tightly and productively. The native-like ATP binding affinity observed for the TrpRS 
Urzyme in tryptophan activation might be supportive of its becoming a potential 
candidate for the ancestral Urzyme.  
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Figure 21: In silico resurrection of the connecting peptide 1 (green spheres) 
wrapping around the core TrpRS Urzyme that binds tryptophan in the amino 
acid binding pocket (Carter, unpublished). 
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Conclusion 
The solubilized redesigned TrpRS Urzyme tryptophan activation activity is further 
characterized through determination of Michaelis-Menten constants. It is striking that 
this 130 amino acid long peptide possesses a native-like ATP binding affinity but a 
103-fold weaker affinity to the cognate substrate, tryptophan. This indicates that the 
removed domains might be crucial for amino acid specificity. More importantly, 
considering the TrpRS Urzyme a potential candidate for the ancestral enzyme and 
CP1 and CTD later insertions in evolution, the addition of these two domains would 
enhance the observed weak affinity for tryptophan. It is possible that the primitive 
Urzyme was able to bind ATP tightly but unable to distinguish its cognate amino acid 
efficiently. Activation of non-cognate amino acids, especially the structurally closely 
related tyrosine, either in the absence or presence of CP1 and CTD, is to be further 
investigated.  
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Aminoacyl-tRNA synthetases participate in many crucial biological processes 
employing different activities beside their canonical aminoacylation role in protein 
synthesis. These enzymes can be potential targets to treat patients suffering from a 
variety of diseases including cancer, Alzheimer, autoimmunity, etc. It is important to 
study the intramolecular interactions within the enzyme to understand the catalytic 
mechanism. Furthermore, investigating the question of how two contemporary class I 
and class II aaRS might have emerged simultaneously and then evolved separately 
would shed light on the involvement of these enzymes in current pathways and 
perhaps allow the prediction of new functions.  
Chapter 2 describes a TrpRS Urzyme constructed by fusing two discrete halves of 
the ATP binding Rossmann fold that shows significant amino acid activation activity.  
This is a uniquely challenging work since instead of making point mutations in the 
intact enzyme, an Urzyme is carved out with extensive deletion and truncation. The 
130-residue long peptide, lacking the connecting peptide 1 and the carboxyl-terminal 
anticodon binding domain that make up 60% the mass of the active dimer, activates 
tryptophan with 65% of the full strength rate acceleration potential (see Chapter 2 
conclusion). It is important to know that this is not contaminating activity from the 
host cell TrpRS since the empty vector control has been substracted as background 
noise. Besides, TrpRS Urzyme has been purified through renaturation from the 
inclusion bodies, separately from the soluble fraction that could contain native form 
of the enzyme. Further experiments are to be done to characterize the Urzyme to 
understand the modular complementation of the removed domains. To that end, I have 
prepared the B, D, ABC and ABD fragments. I will use these to test the influence of 
CP1 and CTD on specificity and activity.  
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More importantly, this Urzyme is an excellent potential candidate for the ancestral 
class I aminoacyl-tRNA synthetase postulated in the Rodin-Ohno hypothesis. The 
procedure I have developed in constructing the TrpRS Urzyme can be used as the 
model to construct other class I Urzymes, as well as a class II Urzymes. Such 
experiments are underway in the lab, and can provide important data to verify the 
validity of the hypothesized sense/antisense relationship. 
Chapter 3 describes the two expression systems used to solubilize the redesigned 
TrpRS Urzyme, in which the pET SUMO produced a substantial amount of total 
protein compared to the original pET42a; however, it was not suitable for obtaining 
soluble protein. A higher molecular weight carrier protein, MBP, was chosen to 
provide stronger solubilizing force. MBP-fused Urzyme was soluble but did not have 
expected tryptophan activation activity. Factor Xa, the protease used to separate the 
carrier protein MBP and the protein of interest, released the Urzyme fragment which 
showed activity in the pyrophosphate exchange assay. Further characterization of 
catalysis by this Urzyme will help unravel the role of the missing domains, and is 
discussed in the next chapter. 
Michaelis-Menten constants were determined through assaying the Urzyme with 
increasing concentrations of the two substrates, ATP and tryptophan. The exchange 
assay assures that the Km values for both substrates actually represent thermodynamic 
affinities. The results with both substrates are somewhat surprising. Binding affinity 
to ATP is relatively unchanged; however, Km for tryptophan is 103 fold weaker, 
indicating that the amino acid binding pocket is impaired in the Urzyme. This is 
probably the result of removing connecting peptide 1, which might have distal 
interactions with the tryptophan binding cavity and perhaps also the GxDQ loop. A 
potential role for CP1 and CTD will be further investigated by in cis and in trans co-
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expression of the two domains ideally with the wild type Urzyme, which would help 
understand the detailed steps in the enzyme evolution. More importantly, TrpRS 
Urzyme can serve as a model system to construct a class II aaRS Urzyme to verify the 
hypothesis proposed by Rodin and Ohno about two coding strands for both classes 
from one ancestral gene.  
The discussed results in the above projects are solely based on the activity assay 
for the amino acid activation. As previously described, after this initial step, the intact 
contemporary enzyme will catalyze the acylation of its cognate tRNA. Wolfson and 
Uhlenbeck have established an assay to characterize the second half of the 
aminoacylation reaction, which is necessary to understand the complete catalytic 
mechanism by TrpRS Urzyme. It is expected that the signal, if detectable, would be 
weak since most of the known structural RNA-interacting elements have been 
removed. Further investigation will be done on which form the construct might 
accommodate. This question is interesting since the dimer interface required for 
dimerization has been deleted together with the connecting peptide 1.  
I have constructed the connecting peptide 1 and the C-terminal anticodon binding 
domain, as well as two genes encoding these domains in cis relative to the core 
Urzyme. These four constructs are to be characterized to unravel the intramolecular 
interactions within the full length enzyme. More importantly, this experiment can 
verify the predicted modular complementation of CP1 and CTD regarding substrate 
recognition and binding enhancement. Besides the in cis co-expression, it seems that 
we should be able to redesign the free CP1 and CTD to test their activity in trans to 
study the nature of the complementation to see whether it is covalent or non-covalent. 
Similar experiments have been done with the GluRS (Lapointe et al., 2009), in which 
the authors have put the truncated CTD back in trans and shown that the activity is 
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enhanced. It is likely that TrpRS Urzyme might have acquired CP1 and CTD as 
additional domain insertion later in evolution. This would further support Rodin-Ohno 
hypothesis about the existence of a small primitive ancestral class I enzyme.  
This class I Urzyme, according to the sense/antisense hypothesis, would have a 
complementary class II Urzyme. There are two different experiments that can be done 
to test this complementarity.  First, based on the gene sequence of TrpRS Urzyme, an 
antisense gene will be constructed. The corresponding peptide will be expressed if 
possible then assayed for amino acid activation activity. The second experiment, 
which is more feasible, is to construct a class II Urzyme from the highly conserved 
motifs of this class then characterize the fragment for aminoacylation activity. The 
Urzyme can be used as a model system to build an ancestral catalytically active core, 
on which presumed later insertions can be added and evaluated for their contributions. 
This work on defining possible intramolecular interactions among structural domains 
would complement the point mutational analyses in understanding evolution at the 
molecular level. 
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